ArticlePostepy dermatologii i alergologii2026
Omalizumab in the management of bullous pemphigoid: a six-month retrospective study.
Article in Postepy dermatologii i alergologii, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Bullous pemphigoid (BP) is the most common autoimmune bullous disease in older adults. However, these patients often require alternative treatments for BP due to comorbidities and use of multiple medications. Aim: To investigate the efficacy of omalizumab in BP patients. Material and methods: The records of patients with clinically, histopathologically, and serologically confirmed BP treated with omalizumab (300 mg monthly) and followed for at least 6 months were retrospectively reviewed. Treatment response was evaluated at 1, 3, and 6 months using the Bullous Pemphigoid Disease Area Index (BPDAI), Pruritus Visual Analogue Scale (PVAS), and treatment response scale (complete response [CR], partial response [PR], or nonresponse). Results: The study included 46 patients (45.7% males) with a mean age at diagnosis of 79.6 years. Before omalizumab treatment, the mean BPDAI was 18 (range: 3-51) and the mean PVAS score was 9 (range: 0-10). Thirteen (28.3%) patients required adjunctive systemic treatment (systemic steroid, azathioprine, dapsone, mycophenolate mofetil, rituximab, intravenous immunoglobulin) in addition to omalizumab. The rate of CR was 67.4% ( Conclusions: BP patients responded well to omalizumab treatment and the CR rate increased with longer use. BPADI scores did not affect the treatment response. Omalizumab appears to be a safe option for BP, either alone or in combination therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.